Modern breast biopsy systems have been deeply embedded into the full-cycle management workflow of breast cancer. Far beyond the singular function of tissue harvesting, they serve as core clinical pivots linking population screening, definitive diagnosis, therapeutic decision-making, mid-treatment efficacy evaluation and long-term post-therapy surveillance, substantially streamlining standardized clinical care pathways.

Core Value in Early Screening and Diagnostic Workup

This remains the most established clinical indication for biopsy devices. With widespread rollout of population-based breast cancer screening globally, numerous imaging abnormalities classified BI-RADS 4 and above are identified annually. The primary clinical mandate of biopsy equipment is to deliver accurate, minimally invasive pathological confirmation.For suspicious microcalcifications detected on screening mammography, digital breast tomosynthesis (DBT)-guided vacuum-assisted biopsy (VAB) stands as the first-line modality thanks to large-volume specimen acquisition and superior calcification retrieval rate, effectively preventing diagnostic delay stemming from inadequate sampling. For sonographically visible breast masses, real-time ultrasound-guided core needle biopsy (CNB) or VAB achieves higher procedural efficiency.By integrating such biopsy modalities, hospitals can build one-stop rapid diagnostic centres, compressing the interval from abnormal screening result to finalized pathological report from weeks down to 24–48 hours. This drastically alleviates patients' screening-related psychological distress and reserves precious lead time for subsequent treatment planning.

Critical Role in Guiding Individualized Therapeutic Decision-Making

Following malignant confirmation, tissue specimens harvested via biopsy constitute the fundamental biological material for comprehensive pathological workup and molecular subtyping. Specimens enable histologic subtyping and tumor grading; more importantly, immunohistochemistry, FISH and multigene assays delineate ER/PR hormone receptor status, HER2 amplification and prognostic genomic scores such as Oncotype DX.These biomarker findings form the evidence base for key clinical decisions including breast-conserving versus mastectomy resection, eligibility for neoadjuvant therapy, and personalized selection of chemotherapy, targeted therapy or endocrine regimens. Accordingly, specimen quality and standardized pre-analytical handling directly govern the precision of treatment planning, serving as an indispensable prerequisite for individualized stratified medicine tailored to identical histologic diagnoses.

Unique Utility for Mid-Treatment Response Assessment During Neoadjuvant Therapy

Locally advanced breast cancer is commonly managed with neoadjuvant chemotherapy or targeted therapy to downstage primary tumors. Accurate mid-cycle efficacy evaluation facilitates timely discontinuation or modification of ineffective regimens. While standalone imaging such as MRI carries inherent diagnostic limitations, image-guided percutaneous biopsy performed after 2–4 cycles of neoadjuvant treatment yields definitive pathological evidence of tumor regression quantified via the Miller-Payne grading system.Paired pre- and post-neoadjuvant histopathology objectively quantifies residual viable tumor burden and identifies patients achieving pathologic complete response (pCR), a powerful long-term prognostic biomarker. Such interim sampling demands superior targeting precision to precisely access the original primary tumor bed.

Minimally Invasive Therapeutic Resection for Benign Breast Lesions

A major expanded clinical application of contemporary VAB platforms is complete minimally invasive excision of benign breast neoplasms. Symptomatic or progressively enlarging benign lesions including fibroadenomas no longer require conventional open surgical excision. Under ultrasound guidance, VAB enables percutaneous en bloc sequential resection via a single tiny skin puncture, delivering minimal scarring, rapid postoperative recovery and superior cosmetic breast outcomes. This functional evolution transforms biopsy instruments from purely diagnostic tools into interventional therapeutic devices, widely adopted within ambulatory day-surgery pathways for benign breast disorders.

Application in High-Risk Population Surveillance and Postoperative Follow-Up

High-risk cohorts with pathogenic BRCA1/2 germline variants or premalignant biopsy diagnoses including atypical hyperplasia and lobular carcinoma in situ require rigorous serial imaging surveillance. Minimally invasive percutaneous biopsy is the gold-standard modality to characterize any newly emerging suspicious lesions identified during monitoring.Likewise, after breast-conserving surgery plus adjuvant radiotherapy, biopsy serves as the definitive differentiator between local disease recurrence and benign postoperative sequelae such as fat necrosis or postsurgical scarring, sparing patients unnecessary overtreatment.

Enabling Translational Research and Novel Technology Validation

High-quality standardized biopsy specimens represent irreplaceable biological resources for preclinical and translational breast cancer research. Biopsy instrumentation facilitates ethically compliant biospecimen banking, organoid cultivation, single-cell sequencing and ex vivo drug sensitivity testing. In parallel, it supplies histopathologic gold-standard reference specimens required for clinical validation of emerging technologies including optical biopsy and in vivo molecular imaging.

Streamlining Ambulatory Day-Care Surgery and Enhanced Recovery Pathways

Refinement of minimally invasive biopsy techniques has accelerated the development of same-day ambulatory breast surgery. Most diagnostic biopsies and benign lesion VAB resection can be completed within outpatient day-surgery centres under local anaesthesia or mild conscious sedation; patients are discharged after several hours of short-term postoperative observation without inpatient admission. This optimizes hospital bed turnover, curbs overall healthcare expenditure and minimizes disruption to patients' daily routine, representing a dominant developmental trend in modern breast surgery.

Conclusion

Breast biopsy devices run through the full breast cancer continuum encompassing prevention, population screening, pathological diagnosis, personalized treatment and translational research. Functioning not only as the cornerstone of definitive diagnosis but also as an interdisciplinary bridge linking radiology and pathology, diagnostic testing and definitive therapy, routine clinical practice and academic research, their deep integration across diversified clinical scenarios underpins a more efficient, precise and patient-centred contemporary breast disease care system.